Ginkgo Bioworks Holdings Future Growth
Future criteria checks 2/6
Ginkgo Bioworks Holdings is forecast to grow earnings and revenue by 30.6% and 21.1% per annum respectively. EPS is expected to grow by 33.5% per annum. Return on equity is forecast to be -40.9% in 3 years.
Key information
30.6%
Earnings growth rate
33.5%
EPS growth rate
Chemicals earnings growth | 17.2% |
Revenue growth rate | 21.1% |
Future return on equity | -40.9% |
Analyst coverage | Good |
Last updated | 15 May 2024 |
Recent future growth updates
Recent updates
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12Ginkgo Bioworks launches Ginkgo Enzyme Services
Dec 08Ginkgo, Lygos team up to produce sustainable biobased specialty chemicals
Nov 11Ginkgo, Draper develop new technologies to detect engineered DNA
Oct 17Ginkgo stock rises on acquisition of French biotech Altar
Oct 04Ginkgo Bioworks: Promising Upside But Not Without Risks
Sep 28Ginkgo Bioworks: May The Ginkgo King Grow
Sep 13Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 332 | -282 | N/A | N/A | 3 |
12/31/2025 | 247 | -431 | N/A | N/A | 7 |
12/31/2024 | 186 | -582 | N/A | N/A | 7 |
3/31/2024 | 209 | -854 | -322 | -294 | N/A |
12/31/2023 | 251 | -893 | -336 | -295 | N/A |
9/30/2023 | 315 | -857 | -405 | -342 | N/A |
6/30/2023 | 326 | -1,224 | -369 | -297 | N/A |
3/31/2023 | 390 | -1,719 | -391 | -323 | N/A |
12/31/2022 | 478 | -2,105 | -304 | -252 | N/A |
9/30/2022 | 528 | -3,530 | -345 | -313 | N/A |
6/30/2022 | 539 | -2,962 | -314 | -290 | N/A |
3/31/2022 | 438 | -2,347 | -264 | -226 | N/A |
12/31/2021 | 314 | -1,830 | -310 | -254 | N/A |
9/30/2021 | 197 | -276 | -218 | -148 | N/A |
6/30/2021 | 133 | -200 | -262 | -168 | N/A |
3/31/2021 | 100 | -175 | -236 | -160 | N/A |
12/31/2020 | 77 | -127 | -194 | -136 | N/A |
12/31/2019 | 54 | -119 | -67 | -45 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DNA's revenue (21.1% per year) is forecast to grow faster than the US market (8.6% per year).
High Growth Revenue: DNA's revenue (21.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: DNA is forecast to be unprofitable in 3 years.